

5.21.228

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	September 6, 2024
<b>Subject:</b>	Niktimvo	<b>Page:</b>	1 of 4

---

**Last Review Date:** June 12, 2025

---

## Niktimvo

### Description

#### Niktimvo (axatilimab-csfr)

---

#### Background

Niktimvo (axatilimab-csfr) is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes and macrophages. Blocking CSF-1R with Niktimvo reduces the levels of these circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophages, as demonstrated by a reduction of nonclassical monocyte counts in nonclinical studies with Niktimvo and inhibits the activity of macrophages in tissues (1).

#### Regulatory Status

FDA-approved indication: Niktimvo is a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (1).

Niktimvo carries warnings for infusion-related reactions and embryo-fetal toxicity. Interrupt or slow the rate of infusion or permanently discontinue Niktimvo based on severity of reaction. Niktimvo may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with Niktimvo and for 30 days after the last dose (1).

The safety and effectiveness of Niktimvo in pediatric patients weighing less than 40 kg have not been established (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	September 6, 2024
<b>Subject:</b>	Nektimvo	<b>Page:</b>	2 of 4

---

---

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Nektimvo may be considered **medically necessary** if the conditions indicated below are met.

Nektimvo may be considered **investigational** for all other indications.

## Prior-Approval Requirements

### Diagnosis

Patient must have the following:

1. Chronic graft-versus-host disease (cGVHD)
  - a. Patient has received at least two prior lines of systemic therapy

**AND ALL** of the following:

- a. Patient weight  $\geq 40$  kg
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Nektimvo and for 30 days after the last dose

---

## Prior – Approval *Renewal* Requirements

### Diagnosis

Patient must have the following:

1. Chronic graft-versus-host disease (cGVHD)
  - a. **NO** disease progression or unacceptable toxicity

**AND ALL** of the following:

- a. Patient weight  $\geq 40$  kg

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	September 6, 2024
<b>Subject:</b>	Nektimvo	<b>Page:</b>	3 of 4

- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Nektimvo and for 30 days after the last dose

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity      6 vials per 84 days

Duration      12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Nektimvo (axatilimab-csfr) is a colony stimulating factor-1 receptor-blocking antibody indicated for the treatment of patients with chronic graft-versus-host disease who have received at least two prior lines of systemic treatment. Nektimvo carries warnings for infusion-related reactions and embryo-fetal toxicity. The safety and effectiveness of Nektimvo in pediatric patients weighing less than 40 kg have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Nektimvo while maintaining optimal therapeutic outcomes.

References

1. Nektimvo [package insert]. Wilmington, DE: Incyte Corporation; August 2024.
2. NCCN Drugs & Biologics Compendium<sup>®</sup> Axatilimab-csfr 2024. National Comprehensive Cancer Network, Inc. Accessed on April 23, 2024.

Policy History

Date	Action
------	--------

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	September 6, 2024
<b>Subject:</b>	Nektimvo	<b>Page:</b>	4 of 4

---

September 2024      Addition to PA  
June 2025            Annual review and reference update

**Keywords**

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 12, 2025 and is effective on July 1, 2025.**